Menu
Products & Markets
Overview
Products & Markets
Products
Enzymes
High-performance Microorganisms
Markets
Nutrition
Health
Environmental
Application
Innovation Examples
Application fields
Solutions
Overview
Solutions
Technology expertise
Enzyme Technology
Microbial Strain Development
Bioprocess Development
BRAIN Bioarchive
Bioactives
Services
Our services
We CRISPR for you
Company
Overview
Company
About BRAIN
BRAIN Biotech Group
BRAIN Biotech AG
Management
Contact
Corporate Culture
Investors
Overview
Investors
Management
BRAIN Biotech at a Glance
Information
Share
Financial News
Publications / Presentations
Financial Highlights
Capital Markets Day
Merger Information
ESG & Sustainability
ESG | Sustainability
Corporate Governance
Compensation
Statement of Conformity
Equity Story
Equity Story & more
FAQs and Glossary
Dates and Events
Annual General Meetings
Financial Calendar
Investors Events
Request Information
Media & News
Overview
Media & News
Information
News & Views
Press Releases
Events
Resources
Press Images
Publications / Presentations
Career
Overview
Career
Work at BRAIN Biotech
Job Advertisements
Start at BRAIN Biotech
Opportunities for University Students
Opportunities for School Students
BRAIN Biotech Network
Alumni
Contact
Search
EN
DE
Contact
Search
EN
DE
Investors
Equity Story & more
Equity Story - Reason 4
Reason 1
Reason 2
Reason 3
Reason 4
Reason 5
Reasons to invest
Reason No. 4: We have an attractive portfolio of products, biotechnology solutions and processes
We possess extensive and well-founded knowledge concerning enzymes, microorganisms, cell-based test systems, and bioactive natural compounds. An interdisciplinary approach enables us to conceive and develop completely new products and services for our customers.
We do not limit ourselves to individual technologies and methods, but instead leverage our broad technology portfolio.
Bioinformatics forms a central element of our R&D expertise for faster and better solutions. In addition to our employees’ experience, we rely here on state-of-the-art technologies in the machine learning and artificial intelligence areas.
The targeted modification and programming of cells is one of BRAIN Biotech’s core competencies. In this context, we deploy all commercially available technologies as well as our proprietary nucleases G-dase M® and G-dase E® for genome editing.
We are an expert solution provider for industry – from research and the scaling up of industrial biological processes to the production of enzymes and proteins.
More than thirty years of experience, around 600 available products for our B2B customers, and over 200 successfully completed industrial cooperation projects are strong testimony to our success.
→
Further reasons
Share this page
Share on Xing
Share on LinkedIn
Share via Email